The Design and Synthesis of a New Class of RTK/HDAC Dual-Targeted Inhibitors
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Design and Synthesis of a New Class of RTK/HDAC Dual-Targeted Inhibitors
Authors
Keywords
-
Journal
MOLECULES
Volume 18, Issue 6, Pages 6491-6503
Publisher
MDPI AG
Online
2013-06-04
DOI
10.3390/molecules18066491
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The discovery of colchicine-SAHA hybrids as a new class of antitumor agents
- (2013) Xuan Zhang et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Chimerically designed HDAC- and tyrosine kinase inhibitors. A series of erlotinib hybrids as dual-selective inhibitors of EGFR, HER2 and histone deacetylases
- (2012) Thomas Beckers et al. MedChemComm
- BB, a new EGFR inhibitor, exhibits prominent anti-angiogenesis and antitumor activities
- (2010) Qi-Ming Sun et al. CANCER BIOLOGY & THERAPY
- CUDC-101, a Multitargeted Inhibitor of Histone Deacetylase, Epidermal Growth Factor Receptor, and Human Epidermal Growth Factor Receptor 2, Exerts Potent Anticancer Activity
- (2010) Cheng-Jung Lai et al. CANCER RESEARCH
- Inhibitors of HDACs - Effective Drugs Against Cancer?
- (2010) S. Muller et al. CURRENT CANCER DRUG TARGETS
- Macrocyclic Histone Deacetylase Inhibitors
- (2010) Sandra C. Mwakwari et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors
- (2010) Cliona Grant et al. Expert Review of Anticancer Therapy
- Discovery of 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDC-101) as a Potent Multi-Acting HDAC, EGFR, and HER2 Inhibitor for the Treatment of Cancer
- (2010) Xiong Cai et al. JOURNAL OF MEDICINAL CHEMISTRY
- Novel Chimeric Histone Deacetylase Inhibitors: A Series of Lapatinib Hybrides as Potent Inhibitors of Epidermal Growth Factor Receptor (EGFR), Human Epidermal Growth Factor Receptor 2 (HER2), and Histone Deacetylase Activity
- (2010) Siavosh Mahboobi et al. JOURNAL OF MEDICINAL CHEMISTRY
- Vorinostat enhances the cytotoxic effects of the topoisomerase I inhibitor SN38 in glioblastoma cell lines
- (2010) Bhaswati Sarcar et al. JOURNAL OF NEURO-ONCOLOGY
- Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease
- (2010) James E. Bradner et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Design of Chimeric Histone Deacetylase- and Tyrosine Kinase-Inhibitors: A Series of Imatinib Hybrides as Potent Inhibitors of Wild-Type and Mutant BCR-ABL, PDGF-Rβ, and Histone Deacetylases†
- (2009) Siavosh Mahboobi et al. JOURNAL OF MEDICINAL CHEMISTRY
- Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis
- (2009) F. Bruzzese et al. MOLECULAR CANCER THERAPEUTICS
- HDAC2: a critical factor in health and disease
- (2009) Oliver H. Krämer TRENDS IN PHARMACOLOGICAL SCIENCES
- Histone deacetylase inhibitors in cancer therapy
- (2008) Min-Jung Lee et al. CURRENT OPINION IN ONCOLOGY
- The ErbB kinase domain: Structural perspectives into kinase activation and inhibition
- (2008) Ron Bose et al. EXPERIMENTAL CELL RESEARCH
- Non-Peptide Macrocyclic Histone Deacetylase Inhibitors
- (2008) Adegboyega K. Oyelere et al. JOURNAL OF MEDICINAL CHEMISTRY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started